

Twenty-Seventh Annual Pharmaceutical and Medical Device Ethics and Compliance Congress

The Leading Forum on Pharmaceutical and Medical Device Ethics and Compliance Issues

Sponsored by the Pharmaceutical Compliance Forum (PCF)

October 13 – 16, 2026 • A HYBRID ONSITE CONFERENCE AND INTERNET EVENT

SPONSORED BY



PRODUCED BY



AGENDA AT A GLANCE

DAY I: TUESDAY, OCTOBER 13, 2026

(Included in standard Congress registration)

11:00 am Registration Opens

1:00 pm – 5:45 pm **IN-DEPTH, HALF-DAY, AFTERNOON FOCUSED SESSIONS** (Included in your Congress registration)

Focused Session 1: Whistleblower Complaints: From Hotline to Resolution: Managing Internal Investigations, Whistleblower Risk & Escalation Decisions

- 1:00 pm** • DOJ/ FCA Enforcement Trends: Lessons from Whistleblower Cases
- 1:30 pm** • Qui Tam Counsel Roundtable
- 2:15 pm** • With Data and AI, Whistleblowers Set Off an FCA Tidal Wave
- 3:30 pm** • Hotline Isn't Enough: Building a Smart Investigations Ecosystem
- 4:15 pm** • Anatomy of an Internal Investigation
- 5:00 pm** • Managing Whistleblower Risk and Internal Escalation

Focused Session 2: Pharmaceutical and Medical Device Advanced Privacy and Security/ Cybersecurity Updates

- 1:00 pm** • The International Association of Privacy Professionals Present: Overview of Key Privacy Compliance Issues for Pharma and Medical Device
- 1:45 pm** • The International Pharmaceutical and Medical Device Privacy Consortium Presents Advanced Strategies for Addressing Privacy and Cybersecurity Issues for Life Sciences Companies
- 2:30 pm** • Companies from the Cybersecurity Working Group, Health Sector Coordinating Council
- 3:30 pm** • Cybersecurity Best Practices for Pharma and Device
- 4:15 pm** • Session Faculty Q&A

Focused Session 3: Managing Medical — Commercial Interactions: Strategic Collaboration, Evolving Roles & Risk-Based Governance

- 1:00 pm** • Co-Chair's Introductions & Session Overview
- 1:15 pm** • Strategic Planning Together, Tactical Execution Separately: Practical Case Studies in Medical–Commercial Collaboration
- 2:00 pm** • Beyond Sales Representatives and MSLS: Understanding Emerging Field-Based Roles and Governance Challenge
- 3:15 pm** • Protecting Medical Independence While Enabling Strategic Cross-Functional Collaboration
- 4:00 pm** • Medical–Commercial Boundaries: Congresses, Sponsorships & Promotional Risk
- 4:45 pm** • Have We Become Too Restrictive? Rethinking Medical–Commercial Governance for the Next Era

Focused Session 4: AI in Action: Real-World Compliance Case Studies from the Front Lines of AI Use in Life Science Compliance Departments

- 1:00 pm** • AI Basics, Life Science Industry Ethics and Compliance Applications
- 1:30 pm** • A Brief Overview of the Epsilon and Qordata Annual AI Use Compliance Survey
- 2:00 pm** • Facilitated Case Study Discussion: From Transcript to Insights: How Compliance Teams Are Using AI to Transform Investigations
- 2:30 pm** • Facilitated Case Study Discussion: AI Governing AI: Leveraging Artificial Intelligence to Develop Effective Governance Policies
- 3:15 pm** • Facilitated Case Study Discussion: AI-Assisted Monitoring and Detection of Potential Policy Violations
- 3:45 pm** • Facilitated Case Study Discussion: Agentic AI Use for Continuous Risk Assessment (vs Annual)
- 4:15 pm** • The Unspoken Risk of AI: Moral Outsourcing — and Why “Add Human Judgment” Isn't Enough
- 5:00 pm** • The Health Care Compliance Association Presents: Advanced Strategies in Using AI to Monitor and Improve Compliance: Lessons from Other Healthcare Sectors

Focused Session 5: GP 101: A Primer on the Fundamentals of Government Pricing for Compliance Officers & The Evolving Pricing and Contracting Landscape: What Compliance Officers Need to Know

- 1:00 pm** • Chair's Introductions & Session Overview
- 1:15 pm** • GP 101: A Primer on the Fundamentals of Government Pricing for Compliance Officers
- 4:00 pm** • The Evolving Pricing and Contracting Landscape: What Compliance Officers Need to Know

Agenda continued next page

AGENDA AT A GLANCE, CONTINUED

DAY II: WEDNESDAY, OCTOBER 14, 2026

7:00 am Registration Opens & Networking Breakfast in Exhibit Hall

8:00 am – 8:50 am MORNING MINI SUMMITS: GROUP 1

MS1: Compliance Independence in the Real World: Governance Models That Work

MS2: Data Analytics and Compliance Monitoring in an AI-Powered World

MS3: Evolution of Patient Finding Activities

MS4: First Product Launch: Policy Development Strategies and Techniques

MS5: Manufacturer–Specialty Pharmacy Relationships: Managing Compliance Risk in Specialty and Rare-Disease Commercial Models

9:00 am – 9:50 am MORNING MINI SUMMITS: GROUP 2

MS6: From Pronouncements to Practice: Understanding DOJ Enforcement Priorities

MS7: Boring is Risky! Want Stronger Ethics and Compliance Engagement? Train & Communicate Colorfully

MS8: The Agentic Compliance Function of the Future

MS9: On the Front Lines: Navigating Field Force & Sales Compliance Risk

MS10: The State of Medical Device Compliance: Annual Industry Roundtable

MS11: Designing HCP Engagement with Transparency Built In

9:50 am – 10:10 am NETWORKING BREAK (in the Exhibit Hall)

10:10 am – 11:00 am MORNING MINI SUMMITS: GROUP 3

MS12: Compliance and M&A: Why Early Engagement Matters

MS13: Pending

MS14: The State We're In: Legal Trends Reshaping Pharmaceutical Compliance

MS15: External Funding Risks and Mitigation: Latest Trends in Exhibit & Display and Sponsorship Requests

MS16: Beyond the Questionnaire: Building a Risk-Based Third-Party Management Program That Actually Works

MS17: Navigating Today's Enforcement Landscape with Culture, Data, and Ethics

11:10 am – 12:00 pm MORNING MINI SUMMITS: GROUP 4

MS18: Risk Advantage: How Resilient Organizations are Capturing Opportunity through Uncertainty

MS 19: View from the Top: Practical Advice for Accelerating Your Compliance Career

MS 20: Direct-to-Consumer (DTC) Models: Emerging Compliance Risks and Governance Considerations

MS 21: Fair Market Value: Practical Strategies and Targeted Insights for Building Defensible FMV Frameworks

MS 22: Swipe Right on Privacy: Navigating the State Privacy Law Landscape

MS 23: Agentic Risk Management: Transforming Compliance Across Key Business Processes

12:00 pm – 1:00 pm NETWORKING LUNCHEON

OPTIONAL SMALL AND MID-SIZED LIFESCIENCE COMPANIES LUNCHEON

Grab your box lunch and join a luncheon discussion designed for emerging and smaller life sciences companies that have limited to no existing compliance program elements. The focus is on helping compliance leaders determine where to begin and how to build a program in a practical, risk-based way.

The discussion will address questions such as:

- Which risks should be prioritized first?
- When should key compliance program elements and controls be implemented?
- How do you build a roadmap that aligns with the company's stage of growth?
- How do you maximize limited resources while establishing an effective compliance program?

1:00 pm – 5:45 pm

PHARMA/DEVICE CONGRESS OPENING PLENARY SESSION

1:00 pm

Welcome and Introduction: PCF Board

1:15 pm

C-Suite Keynote Welcome Fireside Chat

1:45 pm

Keynote Annual OIG Update

2:30 pm

Keynote US DOJ Criminal Division Update Fireside Chat

3:00 pm

Tech & Human-in-the-Loop Compliance (Why Human Judgment Matters More Than Ever)

3:30 pm

Networking Break in the Exhibit Hall

4:00 pm

The Next Generation of Compliance: Leveraging Data to Stay Ahead of Risk

4:30 pm

Integrated Risk Transformation in Pharma/Medical Device: From Compliance Burden to Strategic Advantage

5:00 pm

Annual Chief Compliance Officers Fireside Chat

5:45 pm

Opening Plenary Session Adjournment

5:45 pm – 6:45 pm

NETWORKING RECEPTION

DAY III: THURSDAY, OCTOBER 15, 2026

7:00 am

Registration Opens: Breakfast Buffet in Exhibit Hall

PCF CHIEF COMPLIANCE OFFICER ROUNDTABLE *(PCF-Sponsored, Exclusive Invitation-Only, Closed-Door Session)*

8:00 am	CCO Roundtable Welcome and Introductions	10:00 am	Executive Breakout by Company Size — Part 2
8:15 am	Future of the Compliance Profession in an AI Driven Environment	10:40 am	Demonstrating the Evolving Value Proposition of the Compliance Function
9:00 am	Executive Breakout by Company Size — Part 1	11:55 am	Wrap-up
9:40 am	Networking Break	12:00 pm	Adjournment

8:00 am – 8:50 am

MORNING MINI SUMMITS: GROUP 5

MS24: Identifying and Managing Risk Associated with AI

MS25: A Look Under the Hood: Exploring PBM and Payer Arrangement Risks and Emerging Reporting Requirements

MS26: From Speak-Up to Proof: Turning DOJ and OIG Expectations into Defensible, AI-Enabled Compliance Operations

MS27: Speaker Programs in 2026: Practical Legal and Compliance Considerations for Executing from Beginning to End Amid Ongoing Scrutiny

MS28: Pending

9:00 am – 9:50 am

MORNING MINI SUMMITS: GROUP 6

MS29: Building the Compliance Operating Model for What's Next

MS30: Leveraging AI for More Efficient and Effective Investigations

MS31: Compliance Considerations, Enforcements and Guidelines on Social Media Activities

MS32: Building a Compliance Roadmap: Practical Strategies for Scaling Compliance Programs

MS33: Fair Market Value in Flux: Navigating Complex Fee Arrangements, HCP & Patient Engagement, and Influencer Compensation Risks

MS34: Future-Proofing the Compliance Function: Operating Models for an AI-Enabled World

9:50 am – 10:10 am

NETWORKING BREAK (in the Exhibit Hall)

10:10 am – 11:00 am

MORNING MINI SUMMITS GROUP 7

MS35: Unstructured Data and Advanced Monitoring Strategies

MS36: Pending

MS37: Pending

MS38: Emerging Commercial & Market Access Risk in Life Sciences: Navigating Innovation, Compliance, and Evolving Access Models

MS39: From Oversight to Partnership: Strengthening Collaboration Between Compliance and the Business

MS40: Digital Ecosystem Considerations for Pharmaceutical Companies

11:10 am – 12:00 pm

MORNING MINI SUMMITS GROUP 8

MS41: Holistic, Ongoing Monitoring Case Studies in Compliance

MS42: Compliance Considerations for Rare Disease Products

MS43: Effectively Leveraging Post-Investigation Mitigation to Create a Narrative of Continuous Improvement

MS44: Transparency Reporting; Update on the Centers for Medicare and Medicaid Services Open Payments Program

MS45: Can Learning Data Reduce Risk? Using Measurement to Drive Defensible, Risk-Based Compliance Training

MS46: AI in Clinical Practice: Compliance, Governance & FDA Oversight

12:00 pm – 1:10 pm

NETWORKING LUNCHEON (with Dessert and Coffee in the Exhibit Hall)

12:10 pm – 1:00 pm

LUNCHEON MINI SUMMITS GROUP 9

MS47: Direct-to-Consumer (DTC) Models in the Pharmaceutical Space

MS48: ROI of AI: Separating Value from Hype

MS49: Lean, Credible, Defensible: Compliance Programs That Work Without Big Budgets

MS50: Pending

MS51: Collaborating to Create Lasting Solutions During and After Monitoring or Investigations

MS52: Annual FDA Office of Prescription Drug Promotion Update

1:10 pm – 5:15 pm

CLOSING PLENARY SESSION

1:10 pm

Welcome and Introduction: PCF Board

1:15 pm

Keynote Annual DOJ Civil Division Update Fireside Chat

1:45 pm

Investigations, Enforcement and Prosecutions Roundtable

2:15 pm

Updates from AdvaMed, BIO and PhRMA

2:45 pm

*Market Access in 2026 and Beyond: A Shifting Compliance Landscape

3:15 pm

Networking Break in Exhibit Hall

3:45 pm

Burgeoning Compliance Risks

4:15 pm

AI and the Evolving Compliance Function

4:45 pm

Managing Risk in Unsettled Times

5:15 pm

CLOSING PLENARY SESSION ADJOURNMENT

Agenda continued next page

AGENDA AT A GLANCE, CONTINUED

DAY IV: FRIDAY, OCTOBER 16, 2026

8:00 am – 12 pm	INDUSTRY-ONLY COMPLIANCE BEST PRACTICES THINK TANK <i>(Hosted by PCF: Industry-only Session for Pharmaceutical and Medical Device Company Ethics and Compliance Professionals and In-house Counsel only)</i>
8:00 am	Welcome and Introductions
8:15 am	OPEN
9:15 am	Open Discussion Forum
10:00 am	Inside the New DOJ Initiative: The Rising Importance of Data Miners
10:15 am	OPEN
11:15 am	OPEN
11:45 am	OPEN
11:55 am	Wrap Up
12 pm	CONGRESS ADJOURNMENT